SUD Treatment Tips Using Integrative Chiropractic Care

Unlock the potential of SUD treatment combined with integrative chiropractic care for a comprehensive approach to health and recovery.

Abstract: A New Era in Substance Use Disorder Care

Welcome to Health Voice 360. I’m Dr. Alexander Jimenez, and in my years of practice as both a Doctor of Chiropractic (DC) and a Family Nurse Practitioner (FNP-APRN), I’ve witnessed the profound impact that substance use disorders (SUDs) have on individuals, families, and our communities. As a clinician with dual qualifications, my practice is fundamentally rooted in a holistic and integrative understanding of human health. At Health Voice 360, we witness daily how interconnected the body’s systems are and how social, environmental, and biological factors converge to shape an individual’s health journey. This is particularly true in the complex and often misunderstood field of substance use disorders (SUDs). The landscape of addiction medicine is undergoing a profound, seismic shift, moving away from fragmented, often stigmatizing approaches toward a more integrated, compassionate, and evidence-based model of care. This educational post guides you through this new frontier, synthesizing the latest research from leading experts in the field with my clinical observations to provide a comprehensive roadmap for understanding and managing SUDs in today’s healthcare environment.

Our discussion begins by highlighting the unique and expanding role of Nurse Practitioners (NPs) in SUD care. As the NP profession grows at an unprecedented rate, these highly skilled clinicians are becoming central figures in providing accessible, high-quality addiction treatment. We will examine how the core tenets of NP education—holism and patient empowerment—make them exceptionally suited for this work, and clarify the evolving scope of practice, including the pivotal elimination of the X-waiver for buprenorphine prescribing. From there, we will navigate the diverse settings where SUD care is delivered, exploring the importance of continuity of care from acute hospitals to community clinics. I will share insights on strategies like co-locating services and using “bridge” prescriptions to ensure treatment retention.

We will then turn our attention to populations facing exceptional barriers: justice-involved individuals and peripartum individuals. We will explore the physiological reasons for the high overdose risk after release from incarceration and discuss the systemic failures that contribute to it. For pregnant and parenting individuals, we will analyze federal laws like the Comprehensive Addiction and Recovery Act (CARA), breaking down how punitive state policies can tragically deter women from seeking essential prenatal care. I will offer an evidence-based framework for engaging this population, emphasizing support over criminalization. A significant portion of our journey will focus on best practices and innovative models of care. We will dissect successful integrated programs, the transformative power of inpatient addiction consult services, and the specifics of managing opioid use disorder (OUD) in pregnancy with buprenorphine and methadone. We will also address the unique challenges of treating adolescents with SUDs, explaining the neurodevelopmental factors that make this age group particularly susceptible. Finally, this post will venture into the future of addiction medicine, exploring the promise and pitfalls of genetic testing for SUD predisposition and the groundbreaking research on GLP-1 receptor agonists (like semaglutide) and their potential to revolutionize addiction treatment. Join me as we explore these vital topics, grounded in science and dedicated to advancing patient-centered care.

The Indispensable Role of Nurse Practitioners in Modern Addiction Medicine

As both a chiropractor and a Family Nurse Practitioner, my perspective is shaped by a deep appreciation for holistic, patient-centered care. Addiction medicine is crying out for this approach, and I’ve seen firsthand that Nurse Practitioners (NPs) are uniquely equipped to answer that call. The statistics alone tell a compelling story: with over 258,000 NPs currently practicing in the United States and a projected growth of 45% over the next decade, this profession is a burgeoning force in healthcare. Crucially, more than 70% of these clinicians practice in primary care, the very gateway to the healthcare system for most Americans. This positions NPs on the front lines, making them the first point of contact for countless individuals struggling with a substance use disorder (SUD). Their presence is particularly vital in rural and underserved communities, where they often serve as the sole healthcare providers and bridge critical gaps in access to care.

The Philosophical and Educational Foundation of NP-Led SUD Care

The power of the NP model extends far beyond sheer numbers. The very philosophy underpinning NP education and practice aligns seamlessly with the principles of modern, effective addiction treatment. Let’s break down these core tenets:

• Valuing Patient Autonomy and Self-Determination: In my practice, I’ve seen that recovery cannot be dictated; it must be cultivated. NPs are trained to partner with their patients, not act as paternalistic authorities. We honor the patient’s right to make their own choices, even when those choices are complex or challenging. For a patient with an SUD, this means meeting them where they are, respecting their readiness to change, and supporting their self-defined goals. This collaborative approach fosters trust, a currency that is essential when treating individuals who have often been judged and marginalized by the healthcare system.
• Prioritizing Prevention and Education: A cornerstone of the NP role is empowering patients through knowledge. We don’t just prescribe; we teach. In the context of SUD, this involves comprehensive education on harm reduction, the neurobiology of addiction, the risks and benefits of different treatment options, and strategies for relapse prevention. By demystifying the disease of addiction and providing practical tools, we empower patients to become active participants in their own recovery.
• Mastery of Compassionate, Non-Stigmatizing Communication: Stigma is a formidable barrier to care. Patients fear judgment, punishment, and discrimination, causing them to hide their substance use and delay seeking help. NPs are rigorously trained in therapeutic communication techniques. Motivational Interviewing (MI), for instance, is not just a tool but a core competency woven into NP practice. MI is a conversational style that strengthens a person’s own motivation and commitment to change. It involves asking open-ended questions, practicing reflective listening, and affirming the patient’s strengths and efforts. This non-judgmental stance creates a safe space where patients feel seen, heard, and respected, making it possible for them to disclose their struggles and accept help.

Navigating the Prescribing Landscape: Buprenorphine and Methadone

The ability to prescribe medications is a critical component of SUD treatment. The regulatory landscape for NPs has changed significantly and positively in recent years, though some complexities remain.

The Buprenorphine Revolution: The End of the X-Waiver

One of the most impactful changes in addiction medicine was the federal elimination of the X-waiver requirement for prescribing buprenorphine. For years, this special waiver created a significant barrier, limiting the number of providers who could offer this life-saving medication for opioid use disorder (OUD). Its removal firmly places buprenorphine prescribing within the standard scope of practice for primary care providers, including NPs.

• Physiological Basis of Buprenorphine: To understand why this matters, we must look at the pharmacology. Buprenorphine is a partial opioid agonist. This means it binds to and activates the same mu-opioid receptors in the brain as full agonists like heroin, fentanyl, or oxycodone, but with a much lower intensity. This partial agonism has two key effects:

1. 1. It alleviates withdrawal symptoms and cravings, allowing the patient to stabilize and function.
   2. It has a “ceiling effect.” After a certain dose, taking more buprenorphine does not produce greater euphoria or respiratory depression. This property makes it significantly safer than full agonists and dramatically reduces the risk of overdose.

By prescribing buprenorphine in a primary care setting, I can manage a patient’s OUD alongside their other chronic conditions, like diabetes or hypertension. This integration destigmatizes addiction, treating it as the chronic medical condition it is.

The Role of Methadone and Opioid Treatment Programs (OTPs)

Methadone, in contrast, is a full opioid agonist. While it also binds to mu-opioid receptors to prevent withdrawal and cravings, it does not have a ceiling effect. Because of its potential for misuse and the risk of respiratory depression, federal law mandates that methadone for OUD be dispensed exclusively through licensed Opioid Treatment Programs (OTPs), also known as methadone clinics.

While NPs cannot typically prescribe methadone for outpatient OUD treatment, their role within OTPs and hospital settings is expanding, governed by individual state scope-of-practice laws. In many states, NPs can oversee the initiation and dose adjustments of methadone for hospitalized patients who are admitted for other medical issues but also have an underlying OUD. This is crucial for preventing withdrawal, managing pain effectively, and keeping the patient engaged in care during their hospital stay.

Bridging the Educational Gap

Despite the natural alignment of the NP role with SUD care, a significant challenge persists: limited space for addiction medicine in many NP curricula. The demands of a comprehensive primary care education mean that complex topics like SUD often receive less attention than they warrant. From my own experience and in conversations with colleagues, many new NPs enter practice feeling underprepared to manage the complexities of addiction.

Fortunately, robust pathways exist for NPs to gain the specialized knowledge and skills required.

• Advanced Certification: The Certified Addiction Registered Nurse Advanced Practice (CARN-AP) is a dedicated certification that validates an NP’s expertise in addiction care. Pursuing this certification involves rigorous study and passing a comprehensive exam, ensuring a high level of competency.
• Psychiatric Mental Health Nurse Practitioners (PMHNPs): These NPs complete advanced specialty training and board certification in mental health, which includes in-depth education on the diagnosis and management of SUDs. They are invaluable resources for managing patients with co-occurring mental health and substance use disorders, a very common and complex clinical scenario.

By pursuing these advanced training opportunities, NPs can move beyond basic care and become true experts and leaders in addiction medicine.

Healthcare as a Risk Environment: The Challenge of Stigma

One of the most profound and counterintuitive concepts I’ve had to grapple with in my clinical practice is the idea of healthcare itself as a risk environment for patients with substance use disorders. We envision our clinics and hospitals as places of healing and safety. Yet, for many individuals who use substances, these settings are fraught with fear, judgment, and the potential for harm. This perception is not unfounded; it is rooted in decades of lived experience with systemic stigma and discrimination.

When a patient with an SUD interacts with the healthcare system, they often anticipate negative encounters. They may fear being labeled an “addict,” being treated with suspicion, or even facing legal repercussions. This mistrust has devastating consequences for their health and well-being.

• Delayed Care: Fearing a negative reception, patients will often postpone seeking medical attention until their condition becomes a crisis. A minor infection that could have been treated with a simple course of antibiotics becomes a life-threatening case of sepsis. A nagging cough develops into advanced pneumonia. This delay in care leads to more severe illness, increased morbidity and mortality, and significantly higher costs for the healthcare system.
• Non-Disclosure of Substance Use: The fear of judgment leads many patients to hide their substance use from their providers. This is incredibly dangerous. Without this critical information, I cannot make fully informed clinical decisions. I might prescribe a medication that interacts dangerously with a substance they are using or fail to anticipate and manage withdrawal symptoms. For example, a patient undergoing surgery who does not disclose a heavy alcohol dependency is at high risk for severe, life-threatening alcohol withdrawal post-operatively.
• Minimizing Pain: Patients with a history of SUD are often terrified of being perceived as “drug-seeking.” I have had patients with legitimate, severe pain from fractures or post-surgical recovery who will stoically refuse adequate pain medication for fear of being judged. This leads to unnecessary suffering, poor healing, and a heightened stress response that can actually trigger cravings and relapse.
• Leaving Against Medical Advice (AMA): When a patient feels disrespected, misunderstood, or poorly treated, their instinct is to flee. Hospitalization can be an intensely stressful experience, and if a patient’s withdrawal symptoms are not managed effectively or if they feel stigmatized by staff, they may leave against medical advice. This self-directed discharge interrupts critical treatment, whether for an infection, a cardiac condition, or the SUD itself, and places the patient at extreme risk.

As healthcare providers, we have a moral and ethical imperative to dismantle this risk environment. We must actively cultivate a culture of safety, trust, and compassion. This begins with self-reflection, education on the neurobiology of addiction, and the universal adoption of non-judgmental, person-first language. It means treating addiction with the same empathy and scientific rigor as we treat diabetes or heart disease, transforming our clinics and hospitals from places of risk into true sanctuaries of healing.

A Spectrum of Care: Navigating Treatment Settings

Treating substance use disorders is not a one-size-fits-all endeavor. Each person’s journey to recovery is unique, and the level of support they need can change over time. A comprehensive system of care must offer a continuum of services, allowing patients to move seamlessly between different levels of intensity based on their evolving needs. As shown in the diagram below, primary care often sits at the hub, with various specialized services radiating outward to provide more intensive support when needed.

Let’s explore these key settings in more detail.

• Primary Care: As discussed, this is the cornerstone of long-term management, screening, and treatment initiation for many patients.
• Hospital/Inpatient and Emergency Departments: These acute care settings are often where patients with SUDs present during a crisis—an overdose, a severe infection, or a traumatic injury. These moments represent critical “teachable moments” where a patient may be more receptive to initiating treatment.
• Specialty SUD Treatment Facilities: These include programs like intensive outpatient programs (IOPs), which offer structured therapy for several hours a day, several days a week, and residential treatment facilities (“rehab”), which provide 24-hour structured care in a therapeutic environment.
• Peer Support Networks: Groups like Alcoholics Anonymous (AA), Narcotics Anonymous (NA), and SMART Recovery, as well as certified peer support specialists, offer invaluable community-based support from individuals with lived experience.
• Dedicated Mental Health Services: Essential for treating co-occurring disorders like depression, anxiety, or PTSD, which are often intertwined with and drive substance use.
• Telehealth and Bridge Clinics: These innovative models provide low-barrier access to care, serving as a “bridge” from an acute event (like an ED visit) to long-term treatment, or offering ongoing care for patients in remote areas.

The ASAM Levels of Care: A Framework for Personalized Treatment

To navigate this complex continuum, clinicians need a standardized, evidence-based tool. The ASAM Levels of Care Criteria is the gold standard for this purpose. It provides a holistic framework for assessing a patient and matching them to the appropriate level of care. It is not simply a diagnosis-based system; it is a strength-based, multidimensional assessment.

The ASAM criteria evaluate a patient across six key dimensions:

1. Acute Intoxication and/or Withdrawal Potential: Is the patient currently intoxicated or at risk for severe, life-threatening withdrawal? This determines the need for medical management and monitoring.
2. Biomedical Conditions and Complications: What are the patient’s co-existing medical issues? A patient with severe liver disease from alcohol use, for example, requires a different level of medical supervision.
3. Emotional, Behavioral, or Cognitive Conditions and Complications: Does the patient have a co-occurring mental health disorder, like severe depression or psychosis, that needs to be managed concurrently?
4. Readiness to Change: Where is the patient in their stage of change? Are they contemplative, or are they ready for action? This guides the type of therapeutic intervention.
5. Relapse, Continued Use, or Continued Problem Potential: What is the patient’s risk of relapse? Do they have a history of treatment failure or an unsupportive home environment?
6. Recovery/Living Environment: What is the patient’s social support system? Do they have stable housing and employment? Are they living in an environment where substance use is prevalent?

Based on this comprehensive assessment, a patient is matched to a specific level of care, ranging from Level 0.5 (Early Intervention) to Level 4 (Medically Managed Intensive Inpatient Services).

• Level 4: A hospital or specialized unit for patients with severe, unstable medical and psychiatric conditions requiring 24-hour nursing care and daily physician visits.
• Level 3 (Residential/Inpatient): Includes various sub-levels of 24-hour structured care, from high-intensity residential (3.7) to lower-intensity (3.1).
• Level 2 (Intensive Outpatient/Partial Hospitalization): Provides structured programming for 9 or more hours per week (IOP) or 20 or more hours per week (PHP).
• Level 1 (Outpatient): Standard outpatient services for less than 9 hours per week.

This multidimensional approach moves beyond a simple “rehab or nothing” model, allowing for a truly personalized treatment plan that considers the whole person—their needs, liabilities, strengths, and resources.

Primary Care: The Front Door to SUD Treatment

For most people, primary care is the front door to the entire healthcare system. My role as a Family Nurse Practitioner is built on establishing longitudinal relationships with my patients. I don’t just see them for a single episode of illness; I see them over years, through life changes, celebrations, and struggles. This long-term relationship is an incredibly powerful asset when it comes to treating substance use disorders. It allows me to build a foundation of trust and to engage with patients along their entire trajectory of change.

Meeting Patients Where They Are: The Stages of Change

The Transtheoretical Model of Change provides a useful framework for understanding this trajectory. My intervention will look very different depending on which stage a patient is in:

• Precontemplation: The patient is not currently considering changing their substance use. My role here is not to push or demand change but to gently plant seeds. I might provide harm reduction education, like discussing the importance of using clean needles or carrying naloxone, without judgment.
• Contemplation: The patient is ambivalent about change, weighing the pros and cons. Here, I can use motivational interviewing to explore this ambivalence. I might ask, “What are some of the things you don’t like about using? What are some of the good things you imagine might happen if you made a change?”
• Preparation: The patient has decided to make a change and is planning to take action soon. This is where we can start concrete planning. We might discuss different treatment options, like medications or counseling, and set a target start date.
• Action: The patient is actively modifying their behavior. This is when a primary care provider can initiate medication like buprenorphine, make referrals to therapy, and provide frequent follow-up and support.
• Maintenance: The patient has sustained their change for a period and is working to prevent relapse. My role shifts to ongoing support, monitoring, and celebrating their successes.

This staged approach allows me to tailor my interventions to be maximally effective and supportive, fostering a therapeutic alliance rather than a confrontational one.

The Unmet Potential: Barriers to SUD Care in Primary Care

Despite being the ideal setting for this work, a staggering gap exists between potential and reality. It’s estimated that 86.6% of patients with opioid use disorder who could benefit from medication do not receive it. This is a catastrophic public health failure. Why is this happening?

The elephant in the room is the crisis in our primary care infrastructure. According to 2025 projections:

• Over 77 million people in the U.S. live in a designated Primary Care Health Professional Shortage Area (HPSA).
• Only 5% of the nation’s need for primary care providers is currently being met.
• We would need over 13,000 additional primary care providers to fill the existing gap.

This massive shortage places an immense burden on existing providers. For an already overwhelmed clinician, adding comprehensive SUD care can feel daunting. The barriers they face are numerous and systemic:

• Time Constraints: A standard 15-minute primary care visit is woefully inadequate for the complex conversations and planning required for SUD treatment.
• Low Reimbursement: Historically, reimbursement rates for counseling and care coordination related to SUD have been poor, disincentivizing practices from investing in these services.
• Lack of Referral Pathways: A provider might be willing to start buprenorphine but feel unsupported if they have no reliable mental health or psychosocial support services to refer the patient to.
• Lack of Institutional Support: Without buy-in from clinic management, protected time, and educational resources, providers are left to fend for themselves.
• Fear of Diversion: Concerns that patients might divert their medication (sell it or give it to others) can make providers hesitant to prescribe. While diversion is a valid concern, education reveals that most diversion is for managing withdrawal or helping a friend, not for getting high. The public health benefit of widespread access far outweighs the risks.
• Requirements for Concurrent Counseling: Some outdated models or insurance policies require patients to participate in counseling as a prerequisite for receiving medication. This creates an unnecessary barrier. While psychosocial support is highly beneficial, it should not be mandatory to access life-saving medication.

Best Practices for Integrating SUD Care into Primary Care

Overcoming these barriers requires a systemic shift toward integrated, team-based models. A systematic review identified four common components of successful programs:

1. Offering Pharmacologic Therapy: Making medications like buprenorphine and naltrexone readily available on-site.
2. Co-located Psychosocial Services: Having behavioral health counselors, social workers, or therapists integrated into the primary care clinic.
3. Integrated Care and Warm Handoffs: Ensuring seamless communication and collaboration between medical and behavioral health providers. A “warm handoff,” where the PCP physically walks the patient down the hall to introduce them to the counselor, is incredibly powerful.
4. Patient Education and Outreach: Proactively engaging patients and providing them with the information they need to make informed choices.

Successful models often employ nurse care managers as the primary point of contact for patients on buprenorphine. These nurses can handle regular check-ins, coordinate refills, manage urine toxicology screening, and provide ongoing support, freeing up the prescribing provider to focus on more complex medical decisions.

Furthermore, institutions must cultivate SUD champions—providers who are passionate about this work—and support them with protected administrative time and ongoing education. Resources like the Provider’s Clinical Support System (PCSS), a SAMHSA-funded program, offer free training, clinical mentoring, and resources to empower any clinician to treat OUD.

Case Study in Primary Care: James’s Journey to Recovery

Let’s walk through a case that beautifully illustrates these best practices in action.

The Patient: James is a 52-year-old man with a history of OUD, diabetes, and chronic pain. He sees his primary care NP at a Federally Qualified Health Center (FQHC), a setting designed to provide comprehensive care to underserved populations.

The Visit: During a routine follow-up, the NP doesn’t just focus on his blood sugar. Using open-ended, non-judgmental questions, she gently inquires about his history of opioid use and asks if his chronic pain has triggered any cravings. This empathetic approach creates a safe space. James discloses that he has relapsed and is using illicit fentanyl, driven by his uncontrolled pain and depression. He was on buprenorphine before but stopped, thinking he could “do it without support.” Now, he wants help.

The Intervention (Shared Decision-Making):

The NP doesn’t dictate a plan. Instead, she and James engage in shared decision-making.

• They discuss the pros and cons of restarting buprenorphine.
• They review different ways to start the medication, settling on a high-dose initiation strategy (also known as a macro-induction), a modern approach that can quickly stabilize patients using potent synthetic opioids like fentanyl.
• The NP sends the prescription to the co-located pharmacy right there on campus, eliminating a common barrier to access.
• Crucially, they address the drivers of his use: pain and depression. The NP submits referrals to an on-site mental health counselor and a Chronic Pain Cognitive Behavioral Therapy (CBT) group.
• Then, she performs a warm handoff, walking James down the hall and introducing him personally to the counselor he will be seeing. This simple act transforms a faceless referral into a human connection.

The Follow-Up (A Web of Support):

James leaves the clinic not with a single prescription but with a comprehensive, multifaceted plan.

• He has his buprenorphine script in hand and a clear plan for how to start it.
• A pharmacy check-in is scheduled for the next day, and a telehealth follow-up with his NP is on the books. Short-interval follow-up is critical during initiation.
• He has appointments scheduled for both counseling and the pain management group.

In the following days, James successfully transitions onto buprenorphine. It’s challenging—he reports that waiting until he was in moderate-to-severe withdrawal to start the high dose was difficult. This is a common and important clinical observation; preparing patients for the discomfort of this waiting period is key. Once on the medication, however, he feels much better. He and his NP fine-tune his dose via telehealth.

The support network expands. He is introduced by phone to a peer support specialist, someone with lived experience who can offer a unique form of empathy and guidance. In the future, a nurse care manager manages his care, coordinating refills and follow-ups. James begins to address the root causes of his use through therapy and pain management training. He feels hopeful, supported, and proud that he has not used fentanyl in two days. He knows he has a team he can turn to if he struggles.

This case may seem aspirational, especially for those in under-resourced settings. However, it serves as a powerful blueprint. It highlights the importance of treating the whole person, integrating services, leveraging team-based care, and building a support network around the patient. Even if these services aren’t available under one roof, the principles of coordination, warm handoffs (even virtual ones), and addressing the underlying drivers of use remain the gold standard we should all aspire to.

Specialty SUD Treatment and Acute Care Interventions

While integrated primary care is a powerful model, it’s not always sufficient. Many patients require a more intensive level of support that can only be provided in a specialized setting. All clinicians should know their local referral resources and be able to connect patients to a higher level of care when needed.

Specialty SUD treatment encompasses a wide variety of options:

• Intensive Outpatient Programs (IOPs): Offer structured group and individual therapy for several hours a day, multiple days a week, allowing the patient to live at home.
• Residential or Inpatient Rehab: Provide a 24/7 structured, therapeutic environment away from the patient’s usual triggers and stressors.
• Office-Based Addiction Treatment (OBAT): Clinics specializing in outpatient addiction medicine, often focused on medication management with integrated counseling.
• Opioid Treatment Programs (OTPs): The federally regulated clinics where patients receive daily doses of methadone, along with counseling and other support services.

A crucial point to emphasize is that while behavioral interventions are a mainstay of these programs, they should not be a prerequisite for receiving medication. Evidence overwhelmingly shows that medications for opioid use disorder (MOUD)—like buprenorphine and naltrexone—are highly effective on their own at reducing mortality and improving outcomes. Forcing a patient to engage in counseling before they can access this life-saving medication creates an unethical and harmful barrier. The best practice is to offer and encourage behavioral support but provide medication to anyone willing to accept it.

The Hospital as a Teachable Moment: Inpatient Addiction Consult Services

For many patients with severe SUDs, the hospital is an unavoidable point of contact with the healthcare system. An overdose, a serious infection from injection drug use (like endocarditis or cellulitis), or a traumatic injury often leads to an emergency department visit and hospital admission. These moments of crisis are also profound “teachable moments.” A near-fatal overdose or a life-threatening illness can cause an individual to re-evaluate their life, goals, and substance use, making them more open to treatment than ever before. For patients who have avoided healthcare due to stigma, a positive, supportive hospital experience can be transformative.

The gold standard for capitalizing on this opportunity is the inpatient addiction consult service. These are interdisciplinary teams of SUD experts who are called in to see hospitalized patients with substance-related issues. The composition of the team can vary, but it typically includes:

• An Addiction Medicine Clinician: A physician, NP, or PA with specialized training in addiction who can perform assessments, diagnose SUDs, and manage complex withdrawal protocols and medication initiations.
• A Social Worker or Behavioral Health Counselor: Conducts psychosocial assessments (like the ASAM assessment), provides therapeutic interventions (like motivational interviewing), helps the patient set goals, and begins the complex process of discharge planning.
• A Care Coordinator: Focuses on the logistical challenges of connecting the patient to post-discharge care, such as scheduling appointments, navigating insurance authorizations, and arranging transportation.
• A Peer Support Specialist: An individual with lived experience of addiction and recovery. This role is incredibly powerful. The peer can build rapport in ways clinicians often cannot, offering empathetic listening, practical advice, and tangible hope. They can say, “I’ve been where you are, and recovery is possible.”

The impact of these services is well-documented. Care from an addiction consult service has been shown to reduce hospital readmissions and significantly increase the number of patients who not only start but also continue on medications for opioid use disorder post-discharge.

Beyond direct patient care, these services drive system-wide change. They educate other hospital staff (nurses, physicians, surgeons) on best practices for SUD care, help revise hospital policies to be more patient-centered, and champion quality improvement initiatives that reduce stigma and improve outcomes for this vulnerable population across the institution.

Case Study in Acute Care: Lisa’s Hospitalization

Let’s examine how an addiction consult service can wrap around a patient in crisis.

The Patient: Lisa is a 32-year-old woman who presents to the emergency department with a swollen, red, and painful left leg, which has been worsening for a week. She discloses that she uses intravenous and inhaled fentanyl, as well as methamphetamine, daily. Her last use was six hours ago, and she is starting to feel the intensely unpleasant symptoms of opioid withdrawal. She is deeply worried about her dog, who is with a friend who can’t keep him for long. Chart review reveals she has an untreated hepatitis C infection.

The Initial Engagement (The First 24 Hours):

The primary team calls the addiction consult service.

• The Medical Provider: An NP from the consult service meets with Lisa. After a thorough assessment, she is diagnosed with severe opioid use disorder and severe methamphetamine use disorder. They discuss options for managing her withdrawal and treating her OUD. Through shared decision-making, they decide to start methadone to stabilize her acute withdrawal, with a plan to transition her to buprenorphine later in her stay. They also discuss harm reduction strategies and treatment options for her methamphetamine use.
• The Social Worker: The social worker completes a full ASAM assessment to determine the appropriate level of care post-discharge. They use motivational interviewing to address Lisa’s anxiety and help her commit to staying in the hospital for the full course of treatment for her leg infection. For many patients like Lisa, the urge to leave to use or manage life stressors is immense; the social worker’s support is critical in preventing a discharge against medical advice. They begin exploring her goals and start the referral process for a residential treatment program.
• The Peer Support Specialist: The peer meets with Lisa and immediately connects with her on a human level. They don’t just talk about addiction; they talk about her dog. The peer provides active listening and practical help, offering a cell phone and helping Lisa navigate resources to find secure, temporary care for her pet. Addressing a patient’s primary, real-world stressor builds immense trust and shows Lisa that the team cares about her as a whole person, not just a collection of diagnoses.

Ongoing Care and Stabilization:

Two days later, the team’s interventions are paying off.

• Lisa’s opioid withdrawal is stabilized on methadone, and the team begins a low-dose buprenorphine initiation (a “micro-dose” or “Bernese method” induction). This innovative technique allows a patient to start buprenorphine without having first to stop the full agonist and experience severe withdrawal, making it a much more tolerable process, especially for patients on fentanyl or methadone.
• Her leg infection is diagnosed as cellulitis, and she is started on IV antibiotics.
• Her untreated hepatitis C is addressed with a referral for treatment, a critical intervention to prevent long-term liver damage.
• She continues to have cravings for methamphetamine. The team discusses behavioral strategies like contingency management (providing tangible rewards for negative urine screens) and off-label medications that may help reduce cravings.
• The team provides crucial harm reduction education: discussing the risk of fentanyl contamination in the methamphetamine supply, the importance of carrying naloxone, the dangers of using alone, and how to prevent the transmission of infectious diseases by not sharing paraphernalia.

By the time Lisa is ready for discharge, she is not just physically better; she is stabilized on buprenorphine, has a plan for her hepatitis C treatment, is equipped with harm reduction knowledge, and has a confirmed bed at a residential treatment facility. The addiction consult service transformed a medical crisis into a life-changing opportunity for recovery.

Finding Help: Essential Resources

Knowing where to find help is a critical step for both patients and providers. Here are two invaluable national resources:

• SAMHSA Treatment Locator: samhsa.gov – This website allows you to search for licensed and certified SUD treatment facilities by location, level of care, and services offered.
• Buprenorphine Prescriber List: While the X-waiver is gone, many states or organizations still maintain lists of providers who are experienced in prescribing buprenorphine. The SAMHSA locator includes a filter for this, and resources like the PCSS website can also connect you with knowledgeable clinicians in your area.

The Fragile Bridge: Challenges and Best Practices in Care Transitions

A care transition is a patient’s movement from one healthcare setting to another. This could be discharge from a hospital back to the community, a transfer from an intensive outpatient program to a primary care provider for long-term management, or a move from a telehealth clinic to a residential facility. In my clinical experience, these transitions are the most vulnerable points in a patient’s recovery journey. The bridge between settings is often fragile, and far too many patients fall through the cracks.

The Cornerstone of Recovery: Ensuring Seamless Transitions in Care

In my years of clinical practice, both as a chiropractor understanding the body’s structural and neurological integrity and as a nurse practitioner managing complex medical conditions, I have seen one principle hold above all others: continuity of care is paramount. This is never more critical than when supporting individuals on their journey to recovery from a substance use disorder. A fragmented, disjointed healthcare experience can be the single greatest barrier to long-term success. Conversely, a system designed to provide seamless, uninterrupted support can be the foundation for lasting recovery.

Recent findings from leading researchers have validated this clinical observation with robust data. They have found that structuring programs to ensure a consistent presence of providers between acute and community settings significantly improves patient outcomes. Imagine a patient who has just been stabilized in the hospital after a non-fatal overdose. This is a moment of profound vulnerability and, often, a newfound willingness to engage in treatment. If the provider who initiated their care in the hospital—perhaps starting them on buprenorphine to manage withdrawal and cravings—is the same person they see for their follow-up appointment in a community “bridge clinic,” a powerful connection has already been forged. This isn’t just about convenience; it’s about trust. The patient has already established a rapport with this clinician, shared their story, and received compassionate care. They are far more likely to feel safe, understood, and motivated to continue their treatment journey with that provider, thereby increasing retention in care.

This is why, in my hospital-based practice, I make bridge prescriptions standard care. When a patient is discharged after being started on a medication for substance use disorder, they are entering a precarious transitional period. They need to navigate scheduling follow-up appointments, arranging transportation, and potentially dealing with insurance hurdles. It is unrealistic and frankly dangerous to expect them to accomplish all of this in just a day or two. Therefore, providing at least a two-week supply of their medication, such as buprenorphine, acts as a crucial safety net. It gives the patient the breathing room they need to connect with community resources without the added stress and physiological torment of impending withdrawal. This simple, proactive measure can make the difference between a successful transition and a relapse.

Why Transitions Fail: Systemic Barriers and Silos

The challenges are numerous and deeply embedded in the structure of our healthcare system:

• Care Silos and Communication Breakdowns: Different treatment agencies and hospital departments often operate in their own bubbles, using different electronic health records and having no established lines of communication. Critical information about a patient’s medication plan, follow-up appointments, and social situation is often lost in translation or never transmitted. A patient is discharged from the hospital on a Friday afternoon with a 7-day script for buprenorphine, but their first appointment with their new outpatient provider isn’t for two weeks. That one-week gap is a recipe for relapse.
• Stigma: Stigma doesn’t just affect the patient; it can affect inter-agency collaboration. A primary care office may be hesitant to accept a referral from a “methadone clinic,” or a residential facility may have biases against patients on medication-assisted treatment.
• Staff and Resource Shortages: The same workforce shortages that plague primary care also affect specialty treatment. There aren’t enough community providers, care coordinators, or peer specialists to manage the volume of patients needing follow-up.
• Lack of Patient Resources: Patients discharged from the hospital or residential treatment often face immense personal challenges. They may lack stable housing, transportation to get to appointments, a phone or internet access for telehealth visits, or the financial resources to pay for medications.
• Insurance Barriers: Navigating insurance is a nightmare for everyone, but it can be an insurmountable obstacle for a patient in early recovery. Prior authorizations for medications, coverage gaps between different plans, and narrow networks that exclude needed providers can derail a carefully constructed discharge plan in an instant.

Building a Stronger Bridge: Best Practices for Seamless Transitions

A scoping review of transitions from acute to community settings identified several best practices that I have found to be highly effective in my own practice. The overarching theme is the need for proactive, intentional coordination.

Leverage Existing Community Partnerships

We cannot do this work alone. Hospitals, clinics, and treatment agencies must proactively build relationships with one another. This means:

• Establishing formal memoranda of understanding (MOUs) between organizations.
• Creating shared communication protocols and designated points of contact.
• Holding regular inter-agency meetings to discuss shared patients and systemic challenges. When the inpatient social worker has the intake coordinator’s direct cell phone number at the local IOP, problems get solved quickly.

By building a collaborative ecosystem of care, we create a safety net that can catch patients before they fall.

The Power of Co-Location and Patient Preference

To further strengthen this supportive ecosystem, leading researchers strongly advocate co-locating services. This is a model I have seen work wonders in practice. When a patient can access SUD treatment, mental health counseling, and social support services all under one roof, we dramatically lower the barriers to comprehensive care. The logistical and psychological burden of traveling to multiple appointments at different locations can be overwhelming for anyone, let alone someone in early recovery. By integrating these services, we create a one-stop shop for wellness, fostering a sense of community and making it easier for patients to access the full spectrum of support they need. This model acknowledges that addiction rarely exists in a vacuum; it is often intertwined with mental health conditions, housing instability, unemployment, and food insecurity. Addressing these co-occurring challenges in a coordinated fashion is essential for holistic healing.

Furthermore, we must honor patient preference in the modality and location of care. The one-size-fits-all approach is obsolete. Modern healthcare must be flexible and person-centered. For a single parent with limited access to childcare or someone with mobility issues, telehealth can be a lifeline. Connecting with a provider from the privacy and convenience of their own home can eliminate insurmountable obstacles to attending in-person visits. This flexibility respects the patient’s circumstances and empowers them to take an active role in their recovery.

Finally, the role of care navigators cannot be overstated. These are professionals with specialized knowledge of the intricate web of community resources available. They act as a guide, helping patients navigate the often-confusing transition from an acute care setting back into the community. Programs that recognize the value of these navigators and fund their services are making a direct investment in reducing relapse rates and improving long-term health outcomes. These individuals are the connective tissue of a well-functioning recovery ecosystem, ensuring that no patient falls through the cracks.

Optimizing Your Wellness- Video

Overcoming Unique Barriers: Justice-Involved Individuals

Certain populations face even greater peril in these transitions of care. Justice-involved individuals, particularly those just released from carceral settings like jail or prison, face a perfect storm of risk factors that lead to devastating outcomes. The statistics are stark and sobering: overdose is a leading cause of death following release from prison. As clinicians, we have a duty to understand the multifaceted reasons behind this tragedy and to advocate for and implement systems that can prevent it.

The Physiology of Post-Incarceration Overdose Risk

The primary biological driver of this heightened risk is the loss of opioid tolerance. When an individual who has been using opioids regularly is incarcerated, they are often forced into abrupt cessation. Over weeks or months, their body’s physiological tolerance to the drug diminishes significantly. The ?-opioid receptors in their brain, which had become desensitized and downregulated due to chronic opioid exposure, begin to return to a more naive, sensitive state.

Upon release, if this individual returns to using the same dose they were accustomed to before incarceration, the result can be catastrophic. A dose that previously produced euphoria might now cause profound respiratory depression, leading to a fatal overdose. This physiological reset is a critical piece of information that is too often missing from pre-release counseling. Individuals are frequently unaware of this dramatically increased sensitivity, making their first use post-release a deadly gamble.

Systemic Failures and Psychological Burdens

Systemic failures and psychological burdens compound this physiological vulnerability.

1. Lack of Access to Treatment: The healthcare system can be a labyrinth to navigate. For someone just released from prison, who may have no established primary care provider and no knowledge of how to schedule an appointment or find a treatment center, the barriers can feel insurmountable. This is where the lack of continuity of care becomes particularly lethal.
2. Interruption of Healthcare and Insurance: Incarceration frequently leads to a loss of health insurance, such as Medicaid. Upon release, there can be a significant lag in re-enrolling, leaving individuals without coverage for medications, provider visits, or emergency care. This interruption creates a dangerous gap in their healthcare safety net.
3. Inadequate Treatment Within Carceral Settings: While progress is being made, medications for opioid use disorder (MOUD) like buprenorphine and methadone are still not universally available in jails and prisons. When they are available, they are often poorly implemented. I have heard from many patients who were maintained on sub-therapeutic doses while incarcerated. For example, a patient who requires 16-24 mg of buprenorphine to control cravings might be given only 4-8 mg. This is not only ineffective but can also be counterproductive. It fails to adequately treat their withdrawal symptoms and cravings, leading them to believe the medication “doesn’t work.” This negative experience can create a significant psychological barrier, making them reluctant to try MOUD again upon release, even when it is the evidence-based, life-saving intervention they need.
4. Psychological Impact: The experience of incarceration often inflicts deep psychological wounds. A pervasive sense of poor self-worth, shame, and hopelessness can erode a person’s motivation to seek help. Combined with a lack of education about the nature of addiction as a treatable medical condition, these feelings can create a cycle of despair that fuels a return to substance use as a coping mechanism.

Addressing this crisis requires a multi-pronged approach: mandating universal access to evidence-based MOUD within all correctional facilities, ensuring pre-release education on overdose risk and loss of tolerance, and establishing “warm handoffs” to community treatment providers before an individual is even released. We must build a bridge from the prison gate directly to the clinic door.

A Compassionate Approach: Peripartum Individuals and Substance Use

Another population at exceptionally high risk for negative outcomes, including fatal overdose, is peripartum individuals. Pregnant and parenting women who use substances face a unique and deeply challenging set of barriers, largely driven by stigma and fear. The healthcare system, which should be a source of safety and support, is often perceived as a threat. These fears are not unfounded and are rooted in societal judgments and punitive policies that can have devastating consequences.

The most common strategy pregnant women use to avoid the detection of their substance use is a tragic one: avoidance of medical care altogether. This decision, born of fear, puts both the mother and the unborn child at significant risk by forgoing essential prenatal monitoring, nutritional guidance, and management of potential pregnancy complications. As healthcare providers, we must first understand the legal and social landscape that creates this fear before we can hope to dismantle it and build the trusting relationships necessary to provide effective care.

Unraveling the Legal Labyrinth: CARA and State Reporting Laws

A common misconception among providers is that any substance use by a pregnant or parenting individual must be reported to Child Protective Services (CPS) as suspected child abuse. This is a critical point that needs clarification. The reality is that, at the federal level, substance use alone does not establish child maltreatment.

The key piece of federal legislation governing this issue is the Comprehensive Addiction and Recovery Act (CARA). CARA’s primary intent is not punitive; it aims to focus on the effects of substance misuse on infants and their families to facilitate early identification and intervention. The law requires healthcare providers to notify child welfare agencies when an infant is born “affected by” substances. However, what is vitally important to understand is that this notification does not need to be in the form of a report of suspected child abuse or neglect.

States implement CARA, and this is where the landscape becomes complicated and often punitive. Each state determines whether a report of a substance-affected infant automatically triggers a formal investigation for abuse and neglect and what the legal repercussions are if maltreatment is confirmed. Unfortunately, despite federal guidance, many states have enacted laws that specifically criminalize substance use during pregnancy. This happens because once a woman becomes pregnant, her body is often viewed less as her own and more as a vessel for the fetus, subjecting her to harsher scrutiny and punishment for her actions.

The Detrimental Effects of Punitive Policies

The result of criminalizing substance use during pregnancy is not improved maternal or infant health; it is the exact opposite. These policies breed fear and drive women away from the very systems designed to help them.

• Increased Risk of Overdose: Punitive policies make it harder for pregnant women to access life-saving treatment like MOUD and harm reduction resources like naloxone. Fear of legal consequences, including incarceration or loss of custody, outweighs the desire to seek help.
• Avoidance of Prenatal Care: The fear that a positive drug test will lead to their baby being taken away is a powerful deterrent. A landmark cross-sectional study published in 2022 provided clear evidence of this phenomenon. The study analyzed data from 4,155 pregnant women who used substances and compared their care-seeking behaviors based on the legal climate of their state of residence. The findings were unambiguous: women who delivered in states with more punitive or stricter mandatory reporting policies initiated prenatal care significantly later, had a lower likelihood of receiving adequate prenatal care, and were less likely to attend a postpartum healthcare visit compared to women in states with less restrictive policies.

In conclusion, the evidence is clear: fear of reporting directly and negatively impacts care-seeking behavior. This fear also extends to engagement in SUD treatment itself. It is a sobering fact that fewer than one in four individuals with opioid use disorder receive any form of treatment during any given month of pregnancy. This is a catastrophic failure of our health and legal systems.

A Framework for Compassionate Engagement

As clinicians, we are on the front lines and can change this narrative. We must shift the paradigm from one of stigma and criminalization to one of treatment and support.

1. Recognize the Consequences of Reporting: Before making a report, consider the potential adverse consequences. A child welfare inquiry can place an immense burden on parents, causing them to lose days of work to comply with appointments and requirements. The psychological stress is enormous.
2. Understand the Trauma of Custody Loss: Losing child custody is not a benign event. It has devastating and lasting effects on both the mother and the child. For the mother, it can be a profoundly traumatic experience that exacerbates mental health issues and substance use. Research has shown a heartbreaking correlation: patients who have their parental rights terminated often have shorter interval pregnancies, suggesting a cycle of trauma and loss that perpetuates itself.
3. Create a Welcoming Environment: If we can change these women’s experience with the healthcare system, they will come to us for care earlier. Regular engagement in prenatal care unequivocally improves outcomes for both mother and baby. We can foster this engagement by offering non-judgmental, person-centered care. The moment a pregnant woman with an SUD walks through my clinic door, I make it a point to say, “Thank you for coming to see me today. I know how difficult it can be to get here, and I appreciate you trusting me with your care.” This simple acknowledgment can break down walls of fear and begin to build a therapeutic alliance.
4. Have Realistic and Honest Discussions: Our role is to provide accurate information, not to pass judgment. We must have a realistic discussion of the risks associated with substance use in pregnancy while simultaneously honoring the patient’s goals and life experiences. This means clearly explaining the evidence-based treatment options, such as MOUD, which are safe and highly effective in pregnancy. It means offering warm handoffs and referrals to treatment programs and other support services.
5. Support the Postpartum Transition: The postpartum period is a time of immense change and vulnerability. We can support women by offering flexibility in follow-up appointments, including telehealth options. We should proactively connect them with resources for transportation, childcare, housing, and food insecurity. A warm handoff—for example, a primary care provider personally calling a mental health counselor with the patient present to facilitate a referral—builds trust and dramatically increases the likelihood of follow-through. By engaging social services and building a scaffold of support around the new mother, we treat the whole person, not just the addiction.

Medications for Opioid Use Disorder (MOUD) in Pregnancy: A Clinical Guide

For pregnant women with opioid use disorder (OUD), the decision to start or continue on medications like buprenorphine and methadone is one of the most important they will make for their health and the health of their baby. As clinicians, we have a responsibility to provide clear, evidence-based counseling to help them navigate this decision.

Both buprenorphine and methadone are considered the gold standard of care and are safe and recommended for use in pregnancy. The fundamental principle I convey to my patients is this: the risk of untreated OUD—characterized by cycles of intoxication and withdrawal—is far greater for both the mother and the fetus than the risks associated with the medication. Unmanaged withdrawal can lead to uterine contractions, decreased placental blood flow, and fetal distress, potentially resulting in miscarriage or premature labor. Continued illicit opioid use carries the risk of overdose, infection, and exposure to unknown and dangerous substances like fentanyl. MOUD stabilizes the mother, eliminates the cycle of withdrawal, reduces cravings, and allows her to focus on her health and pregnancy.

Counseling on Neonatal Opioid Withdrawal Syndrome (NOWS)

A common and understandable concern for expectant mothers is whether the medication will cause their baby to go into withdrawal after birth. This condition is known as Neonatal Opioid Withdrawal Syndrome (NOWS) or Neonatal Abstinence Syndrome (NAS). It is crucial to address this topic head-on with factual and reassuring information.

I explain to my patients that yes, there is a risk of NOWS. The baby is exposed to the medication in utero, and after birth, they may experience withdrawal symptoms as the medication clears from their system. These symptoms can include irritability, tremors, high-pitched crying, feeding difficulties, and sleep problems. However, I emphasize several key points:

• NOWS is treatable and temporary. Pediatric teams are highly experienced in managing it with supportive care (such as swaddling, a quiet environment, and frequent small feeds) and, if necessary, with small doses of medication like morphine to gently wean the baby.
• The benefits of MOUD—preventing maternal relapse, overdose, and the chaos of active addiction—far outweigh the manageable risk of NOWS.
• Crucially, research has consistently shown that NOWS severity is not dose-dependent. This is a vital counseling point. The best dose of buprenorphine or methadone is the one that adequately treats the mother’s withdrawal symptoms and cravings, keeping her stable and safe. Reducing her dose out of fear of NOWS would be counterproductive, as it could lead to cravings, relapse, and far greater dangers.

Navigating Physiological Changes: Dosing in Pregnancy and Postpartum

Pregnancy induces significant physiological changes that impact how drugs are metabolized. As pregnancy progresses, particularly into the third trimester, plasma volume, cardiac output, and hepatic and renal blood flow increase. This leads to an accelerated metabolism of many medications, including buprenorphine and methadone.

What this means clinically is that pregnant women often need higher doses of MOUD as their pregnancy advances to maintain therapeutic stability and prevent the emergence of withdrawal symptoms or cravings. A patient who was stable on 16 mg of buprenorphine in her first trimester might require 24 mg or even 32 mg by her third trimester to achieve the same effect. It is essential to monitor patients closely and adjust their dose based on their reported symptoms, not on a preconceived notion of a “correct” dose.

The period immediately following childbirth presents a new set of challenges. After delivery, the mother’s metabolism begins to return to its pre-pregnancy state. However, the exact rate at which this occurs is not precisely known and varies between individuals; the current evidence suggests it happens somewhere between three and twelve weeks postpartum. This means that the high dose of MOUD she required in late pregnancy may now be too much for her, putting her at risk for oversedation and respiratory depression.

Therefore, postpartum dose reductions should be approached carefully and on a case-by-case basis. It is not a process that can be rushed or standardized. I work closely with my postpartum patients, checking in with them regularly about their symptoms. We collaboratively and gradually make small dose reductions over the 3-to-12-week postpartum window, always prioritizing their stability and safety.

The Proven Benefits of MOUD During Pregnancy

It is important to highlight the overwhelmingly positive outcomes associated with MOUD during pregnancy. Its use is linked to:

• Decreased risk of overdose during both pregnancy and the critical postpartum period.
• Increased engagement in prenatal care.
• Improved birth outcomes, including increased birth weight and gestational age.
• Greater likelihood of the mother retaining custody of her child.

Conversely, research has identified key factors associated with MOUD discontinuation after birth. These include a shorter duration of MOUD while pregnant (reinforcing the importance of starting treatment as early as possible), incarceration, and non-white race (highlighting the impact of systemic racism and health disparities). This data underscores the urgent need to design care systems that specifically address the barriers women, particularly women of color, face in accessing and continuing MOUD in the postpartum period.

Case Study: Applying Best Practices for a New Mother

To bring these principles to life, let’s consider a clinical case.

Patient: Liz, a 32-year-old female, is one day postpartum after the birth of her baby girl. She has a history of OUD with illicit fentanyl use and was started on buprenorphine by a primary care provider during her pregnancy. Her dose was gradually titrated up to a total of 32 mg per day (administered as 8 mg four times daily) during her third trimester to manage her cravings effectively.

Considerations for Post-Discharge Care Transitions:

1. Assess the Mother-Baby Dyad and Social Context: My first step is to understand the entire situation. The postpartum period is overwhelming for any new mother, and for Liz, it is compounded by her recovery journey. Her baby may be monitored in the NICU for several days for NOWS. This creates immense emotional and logistical stress. I need to ask critical questions: Does Liz have stable housing? Does she have transportation to get back and forth to the hospital to be with her newborn? Does she have a social support network—a partner, family, or friends—to help her? Understanding this context is fundamental to creating a realistic and supportive care plan.
2. Offer Flexible and Co-Located Services: Recognizing the demands on her time and energy, I would offer flexible follow-up options, including telehealth visits. If possible, I would connect her with a program that offers co-located services, where she and her baby can receive medical care in the same place, reducing the travel burden and integrating their care.
3. Counsel on Postpartum Dose Reduction: I would have a direct conversation with Liz, explaining that as her body’s metabolism returns to normal, she will likely not need 32 mg of buprenorphine per day. I would frame this not as taking something away, but as a necessary safety measure to avoid sedation. I would tell her, “We are a team in this. I want you to be alert and present for your new baby. We will check in frequently, and together, we will find the dose that keeps you feeling well without making you overly tired.” I would then schedule regular check-ins to monitor for cravings and withdrawal and encourage small, gradual dose reductions over the next 3 to 12 weeks.
4. Scaffold Recovery with Social Supports: Liz’s recovery cannot rest on medication alone. I would immediately engage our hospital’s social work team to connect her with all available resources. This could include:

• • Peer Support: Connecting her with another mother in recovery who can offer lived experience and encouragement.
  • Mental Health Support: A referral for therapy to address underlying trauma or co-occurring mental health conditions.
  • Tangible Resources: Assistance with applications for food resources (like WIC or SNAP), transportation vouchers, and housing programs.

The availability of these resources varies significantly by location and insurance coverage. This highlights how crucial it is for clinicians to be deeply familiar with the local resources in their community. We must be more than prescribers; we must be resource connectors.

The Developing Brain: Treating Substance Use in Adolescents

The final special population I want to focus on is adolescents. While the good news is that overall youth drug use has been on a downward trend, certain factors place today’s teens at unique and significant risk. The landscape they navigate is different from that of previous generations, particularly with the lethal prevalence of illicitly manufactured fentanyl.

As of 2021, a staggering four out of five teens reported feeling overwhelmed, pointing to a widespread mental health crisis that can fuel substance use as a form of self-medication. Furthermore, data shows that 16% of young Americans have misused a prescription medicine, and, alarmingly, less than half (48%) are aware that fentanyl is being used to create counterfeit pills that look identical to legitimate pharmaceuticals like oxycodone or Xanax. This lack of awareness creates a deadly game of Russian roulette with any pill obtained outside of a pharmacy.

However, there is a powerful ray of hope: education works. After being shown targeted information about fentanyl and fake pills, 65% of young Americans reported they would be less likely to consider misusing prescription drugs. This demonstrates that providing clear, factual information is a potent public health intervention.

How Adolescent Treatment Differs from Adult Treatment

Treating adolescents with SUDs requires a specialized approach that acknowledges their unique developmental, social, and psychological stage.

• The Developing Brain: The adolescent brain is a work in progress. The reward system (the limbic system), which drives the pursuit of pleasure and responds to substances, is fully developed. However, the planning center, the prefrontal cortex, which is responsible for impulse control, risk assessment, and executive function, is still maturing and will not be fully developed until the mid-twenties. This neurobiological mismatch creates a brain that is highly sensitive to the rewarding effects of substances but lacks a mature “braking system” to make long-term, healthy choices consistently. They are neurologically wired for impulsivity.
• Different Motivations for Use: An adult’s substance use is often driven by long-standing dependence. For adolescents, the motivations can be more varied and complex. They may be struggling with low self-esteem, using substances to fit in with a peer group, or self-treating underlying anxiety, depression, or other mental health disorders. Body image issues and weight-loss desires can also be motivating factors. Identifying these drivers is key to effective treatment.
• Co-occurring Mental Health Issues and Polysubstance Use: Co-occurring mental health conditions are the norm, not the exception, in adolescents with SUDs. Polysubstance use is also extremely common, which significantly increases the risk of negative consequences, especially overdose from unpredictable drug interactions.
• Different Use Patterns: Adolescent substance use may not always follow a pattern of daily, dependent use. It can be more episodic or experimental. This requires a nuanced approach to treatment and medication decisions.
• Low Treatment Retention: Evidence has consistently shown that, as a group, adolescents have low retention rates in SUD treatment programs. This makes every interaction and every intervention critically important for engagement.
• Parental Involvement and Consent Laws: Depending on the state, there may be a legal requirement for parental involvement for an adolescent to receive treatment. For example, in my state of Oregon, minors aged 14 and older can consent to receive SUD treatment on their own. This doesn’t mean I wouldn’t strongly encourage and facilitate parental involvement where appropriate and safe, but it empowers the adolescent to seek care independently if needed. Providers must know the specific consent laws in their state.

Medication Options for Adolescents with OUD

Our medication options for adolescents are more limited than for adults, and the evidence base is still developing.

• Buprenorphine: This is considered the first-line treatment for OUD in adolescents (ages 12-18) and young adults (ages 18-25). It is officially FDA-approved for ages 16 and up. However, many expert providers, myself included, are using it “off-label” in younger adolescents (as young as age 12) when clinically appropriate, after a thorough risk-benefit discussion with the patient and their family. It is important to be transparent that we lack robust studies on buprenorphine use under age 18, and there is a complete lack of evidence for the use of long-acting injectable buprenorphine, which is not approved for those under 18.
• Naltrexone: This opioid antagonist is FDA-approved for ages 18 and up.
• Methadone: This is also FDA-approved for ages 18 and up and is typically administered only in highly structured opioid treatment programs.

Best Practices in Adolescent Care Transitions

1. Wraparound Care and Resource Knowledge: Whenever possible, we should strive to provide wraparound care, addressing not just the substance use but also the adolescent’s mental health, family dynamics, and educational needs. SUD treatment options for adolescents can be scarce. In my geographic area, there are only a handful of primary care providers willing to prescribe buprenorphine to teens and only a couple of adolescent-specific residential programs. This makes it imperative to know your local area resources inside and out.
2. Address Mental Health and Drivers of Use: A successful treatment plan must identify and address the underlying drivers of use. This means screening for and treating anxiety, depression, and trauma. It involves talking with the adolescent about why they are using substances and collaborating on healthier coping strategies.
3. A Nuanced Approach to MOUD: The evidence is clear that for young adults (ages 18-25), MOUD significantly improves retention in care. By extension, there is a compelling argument that offering MOUD to adolescents under 18 can be a life-saving intervention that keeps them engaged in treatment. However, the decision requires careful consideration, especially for those with episodic use patterns. I always inform my adolescent patients and their parents that for buprenorphine to be effective at preventing overdose, a dose of at least 8 milligrams is generally needed to achieve adequate blockade of the opioid receptors. For a teen who is not opioid-dependent, this dose could cause significant sedation. It’s a complex decision that requires a thorough discussion of the risks and benefits, empowering the family to make an informed choice.
4. Prioritize Harm Reduction and Naloxone: For all adolescents, whether they choose MOUD or not, naloxone distribution is non-negotiable. Empowering teens, their friends, and their families to recognize and reverse an overdose will save lives. We must have open conversations about harm reduction, teaching them never to use alone, to test their drugs for fentanyl if possible, and to always have naloxone on hand. These pragmatic strategies acknowledge the reality of their world and provide them with tools to protect themselves.

The Horizon of SUD Care: Genetics and Novel Pharmacotherapies

The field of addiction medicine is dynamic, with new research constantly pushing the boundaries of our understanding and treatment capabilities. Two areas, in particular, are generating significant excitement and discussion: the role of genetics in SUD predisposition and the potential for a new class of medications to treat addiction.

The Promise and Peril of Genetic Testing

Over the past decade, research has firmly established that genetics play a role as one of multiple factors predisposing an individual to developing a substance use disorder. While the exact extent of this genetic contribution is still being quantified, it is thought to have a moderate effect and interact with environmental, social, and psychological risk factors. Scientists have even begun to isolate specific genes that may be associated with an increased risk for SUDs.

This has led some companies to develop and market genetic tests that claim to identify at-risk individuals. On the face of it, this sounds like a powerful prevention tool. A test that could tell you if you are genetically predisposed to a disease could theoretically allow for early, targeted interventions. However, significant challenges and ethical concerns currently prevent the widespread clinical use of these tests.

• Ethical Concerns: What would we do with this information? There is a substantial risk of creating bias and stigma. Could an individual identified as being “at risk” face discrimination in employment, insurance, or even within their own family?
• Lack of Robust Evidence: No large-scale, well-controlled clinical trials have evaluated the efficacy or clinical utility of these tests. We don’t know if using them actually leads to better outcomes.
• Predictive Limitations: These tests offer probabilistic, not deterministic, results. They can indicate a heightened risk, but they cannot predict with certainty who will or will not develop an SUD. The potential for both false positives (causing undue anxiety) and false negatives (creating a false sense of security) is high.
• Cost and Accessibility: These tests can be expensive and are not widely available or covered by insurance, raising health equity concerns.
• Privacy Concerns: The testing is often performed by third-party companies, raising serious questions about data privacy. Who has access to these highly sensitive genetic results, and how might they be used?

Until these critical ethical, scientific, and privacy issues are resolved, genetic testing for SUDs remains an area of research interest rather than a practical clinical tool.

A New Frontier: GLP-1 Receptor Agonists in Addiction Treatment

One of the most exciting new topics in addiction care revolves around a class of medications originally developed for diabetes and weight management: GLP-1 receptor agonists. This class includes well-known drugs such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity).

GLP-1 receptors are found not only in the pancreas and gut but also in the brain’s reward pathways. By activating these receptors, these drugs appear to modulate the dopaminergic signaling that underlies the rewarding effects of substances, potentially reducing cravings and consumption.

The evidence is still emerging but is incredibly promising.

• A recent randomized controlled trial showed that adults with co-occurring obesity and alcohol use disorder who were receiving a GLP-1 receptor agonist consumed significantly lower amounts of alcohol compared to those on a placebo.
• A compelling set of recent studies by Wang et al. analyzed large-scale medical claims data. They compared patients taking GLP-1 receptor agonists for diabetes to patients taking other classes of anti-diabetes medications. The findings were striking: patients on semaglutide had a significantly lower risk of being diagnosed with or having a relapse of tobacco use disorder, cannabis use disorder, and opioid use disorder.

While this is not yet definitive proof of causation, the strong association found in these large real-world datasets suggests a powerful effect that warrants further investigation through rigorous clinical trials. We will undoubtedly see the evidence for these medications in the treatment of SUDs continue to evolve rapidly in the coming years. It represents a potential paradigm shift, offering a novel pharmacological mechanism to help individuals regain control from addiction.

Thank you for joining me for this comprehensive exploration of modern SUD care.

Summary, Conclusion, and Key Insights

Summary

This educational post, presented from my perspective as Dr. Alexander Jimenez, DC, APRN, FNP-BC, has provided a comprehensive exploration of the modern landscape of substance use disorder (SUD) care, synthesizing the latest research with clinical observations as of August 4, 2026. We began by establishing the rapidly expanding and vital role of Nurse Practitioners (NPs) and the critical importance of continuity of care. We then examined healthcare settings as potential “risk environments” due to stigma and detailed the ASAM Levels of Care Criteria as a tool for personalizing treatment. The discussion navigated diverse settings of care, highlighting best practices for integrating SUD treatment into primary care and the function of inpatient addiction consult services, illustrated with case studies of patients named James and Lisa. The focus then shifted to the unique challenges of vulnerable populations. For justice-involved individuals, we explored factors contributing to overdose post-release. For peripartum individuals, we analyzed how punitive laws, in contrast to the federal CARA law, deter care-seeking. We delved into managing OUD in pregnancy with MOUD, the specialized care of adolescents, and finally, looked toward the future, evaluating genetic testing and the emerging research on GLP-1 receptor agonists like semaglutide as a novel treatment for SUDs.

Conclusion

As of August 4, 2026, addiction medicine stands at a pivotal crossroads. We are moving decisively away from fragmented, judgmental models toward an integrated, compassionate, and evidence-based paradigm. The principles discussed here—empowering advanced practice providers, creating destigmatized environments, personalizing care with frameworks like ASAM, championing continuity, and meticulously managing transitions—are actionable imperatives. By understanding the vulnerabilities of populations like justice-involved individuals, peripartum women, and adolescents, we can tailor interventions to be truly life-saving. The shift from judgment to support, particularly for pregnant women, is a clinical imperative proven to improve outcomes. As we look to the horizon, the potential of genetic insights and novel pharmacotherapies like GLP-1 agonists promises to add powerful tools to our arsenal. Ultimately, effective SUD care is holistic, person-centered, and deeply human. It requires us to be not only prescribers and diagnosticians but also advocates, educators, and unwavering sources of support for those on the difficult but hopeful path to recovery.

Key Insights

• Continuity of Care is Non-Negotiable: A consistent patient-provider relationship across different care settings (hospital to community) is a primary driver of treatment retention and success.
• Punitive Policies Harm, Support Heals: Criminalizing substance use, especially in pregnancy, is counterproductive. It drives individuals away from care and leads to worse health outcomes. A non-judgmental, supportive approach is clinically superior.
• MOUD Dosing Must Be Dynamic: Medication doses for pregnant women must be increased as pregnancy progresses to account for accelerated metabolism and then carefully reduced postpartum on a case-by-case basis to prevent sedation. The dose is not one-size-fits-all.
• Adolescent Care Requires a Neurodevelopmental Lens: Treatment for teens must account for their developing brains, focusing on harm reduction, addressing the underlying drivers of use, and navigating consent laws with care.
• The Future is in Novel Mechanisms: Emerging research on GLP-1 receptor agonists (semaglutide) suggests a groundbreaking new pathway for treating addiction by modulating the brain’s reward system, making it a key area to watch for future clinical practice.

Keywords: Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Care Transitions, Nurse Practitioner (NP), Buprenorphine, Methadone, ASAM Levels of Care, Inpatient Addiction Consult Service, Primary Care Integration, Harm Reduction, Motivational Interviewing, Stigma in Healthcare, Peer Support Specialist, Continuity of Care, Medications for Opioid Use Disorder (MOUD), Peripartum, Pregnancy, Neonatal Opioid Withdrawal Syndrome (NOWS), Justice-Involved Individuals, Adolescent Substance Use, Prefrontal Cortex, Naloxone, GLP-1 Receptor Agonists, Semaglutide, Genetic Testing, Comprehensive Addiction and Recovery Act (CARA), Dr. Alexander Jimenez, Health Voice 360.

References:

• American Association of Nurse Practitioners. (n.d.). NP Fact Sheet. AANP.
• American College of Obstetricians and Gynecologists (ACOG) Committee Opinion on Opioid Use and Opioid Use Disorder in Pregnancy.
• American Society of Addiction Medicine. (n.d.). The ASAM Criteria. ASAM.
• American Society of Addiction Medicine (ASAM) National Practice Guideline for the Treatment of Opioid Use Disorder.
• Chan, C. A., et al. (2019). A Scoping Review of Transitions of Care from Acute to Community Settings for Patients with Substance Use Disorders. Journal of Substance Abuse Treatment.
• Cross-sectional study on punitive policies and prenatal care. (2022). [Citation details for the 2022 study on 4,155 pregnant women would be placed here.]
• Federal Comprehensive Addiction and Recovery Act (CARA), Pub. L. 114–198. (2016).
• LaBelle, C. T., et al. (2016). Office-Based Opioid Treatment with Buprenorphine (OBOT): Statewide Implementation and Modification of a Care-Delivery Model. Journal of Substance Abuse Treatment.
• (n.d.). Provider’s Clinical Support System (PCSS).
• Substance Abuse and Mental Health Services Administration (SAMHSA) Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants.
• Wakeman, S. E., et al. (2017). The Impact of an Inpatient Addiction Consult Service on Treatment of Substance Use Disorders. Journal of General Internal Medicine.
• Wang, W., et al. (Recent studies). [Citation details for the Wang et al. studies on GLP-1 agonists and SUDs would be placed here once formally published and available.]
• Williams, B. (2026). Care Transitions and New Frontiers in SUD Treatment. Presentation.

Disclaimer: This educational post is for informational purposes only and does not constitute medical advice. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. It is based on information available up to the content creation date of August 4, 2026. Medicine is constantly evolving, and this information may not be the most current. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Personal Medical Advice Disclaimer: All individuals are unique, and the content presented here is general information. Do not use it to make decisions about your personal health. You must obtain recommendations and a personalized care plan for your specific situation from your own licensed medical providers. Do not disregard professional medical advice or delay in seeking it because of something you have read here.